Global Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Genes Market, By Indication (Breast Cancer, Ovarian Cancer, Others), Treatment (Platinum-based Chemotherapy, PARP Inhibitors, Surgery, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Genes Market Analysis and Size
The market for the BRCA1 and BRCA2 genes, which cause breast cancer 1 and 2, is expected to expand quickly over the coming years. The industry is being driven by globally increasing rates of cancer incidence and prevalence. According to the American Cancer Society, women in the United States will develop 281,550 new cases of invasive breast cancer and 49,290 new cases of non-invasive breast cancer in 2021. People who inherit harmful mutations in one of these genes are more likely to develop several malignancies. People who inherit a harmful BRCA1 or BRCA2 variant are more likely than those who do not to develop cancer at an earlier age.
Data Bridge Market Research analyses that the breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes market, which is USD 5.62 billion in 2022, is expected to reach USD 11.28 billion by 2030, at a CAGR of 9.10% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Genes Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Breast Cancer, Ovarian Cancer, Others), Treatment (Platinum-based Chemotherapy, PARP Inhibitors, Surgery, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), Akorn, Incorporated (U.S.) Cipla Inc. (U.S.), Pacira BioSciences, Inc. (U.S.), Spectrum Pharmaceuticals, Inc (U.S.), Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (China), Fresenius Kabi AG (Germany)
|
|
Market Opportunities
|
|
Market Definition
Breast cancer genes 1 and 2 (BRCA1 and BRCA2) are responsible for encoding instructions that inhibit tumor cells or stop them from increasing uncontrollably. Additionally, the repair of DNA damage is a function of these genes. BRCA1 and BRCA2 gene mutations can result in breast and hereditary ovarian malignancies. There may also be an increase in malignancies, including prostate and pancreatic.
Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Genes Market Dynamics
Drivers
- Increasing investment in healthcare infrastructure will boost the market growth
The increasing costs of healthcare, which assist in improving its infrastructure, are a significant factor impacting the market for the BRCA1 and BRCA2 genes and their growth rate. The market for the BRCA1 and BRCA2 genes will expand as a result of greater efforts by both public and commercial entities to raise awareness and develop technology. The market for the BRCA1 and BRCA2 genes will expand as a result of high disposable income and a dynamic way of life.
Opportunities
- Rising cases of breast cancer will act as a opportunity
Breast cancer develops in different societies due to various hereditary, environmental, and acquired variables. Genetics, such as predisposing genes to develop this disease, should be considered more in families with a history of breast cancer spanning multiple generations. Early diagnosis of mutation carriers in these genes can be crucial to its prevention. Female screening for predisposing gene variants, which have been observed in breast cancer patients, seems vital due to the disease's significant frequency in half of the world's population. These are the certain factors that propel the market growth.
Restraints/Challenges
- Lack of qualified workers will hinders the market growth
The market for the BRCA1 and BRCA2 genes will face challenges due to a lack of qualified workers and healthcare infrastructure in underdeveloped nations. Additionally, during the projection period of 2023-2030, a lack of knowledge would act as a restraint and further restrict the market's growth rate.
This breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Genes Market Scope
The breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes market is segmented on the basis of indication, treatment, route of administration, end-users, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Breast Cancer
- Ovarian Cancer
- Others
Treatment
- Platinum-based Chemotherapy
- PARP Inhibitors
- Surgery
- Others
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Genes Market Regional Analysis/Insights
The breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes market is analysed and market size insights and trends are provided by country, indication, treatment, route of administration, end-users, distribution channel as referenced above.
The countries covered in the breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominated the breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes market due to the region's significant important companies and established healthcare infrastructure. The prevalence of breast and ovarian cancer is rising, and the number of FDA-approved medications is rising, both of which will accelerate this market's growth rate.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the increasing desire of numerous multinational corporations to increase their presence in this area. The expansion of the healthcare infrastructure will also speed up the market's expansion in this area.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes Market Share Analysis
The breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes market.
Some of the major players operating in the breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Merck & Co., Inc. (U.S.)
- Akorn, Incorporated (U.S.)
- Cipla Inc. (U.S.)
- Pacira BioSciences, Inc. (U.S.)
- Spectrum Pharmaceuticals, Inc (U.S.)
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (China)
- Fresenius Kabi AG (Germany)
- Takeda Pharmaceutical Company Limited (Japan)
SKU-